An Update on Viral Issue in Autism
October 11, 2011 67 Comments
I am writing this 8 days away from my trip to the Ministry of Health in Kiev, Ukraine to work with some of the World’s leaders in neuronal (brain) stem cell research – but more on that in a little bit. First of all let me apologize for being so long in posting. Moving to Georgia and establishing an additional office there has been very taxing on my time. I still have my office in Florida and California as well so I am doing all I can to bring these concepts to as many families as possible.
We have now evaluated approximately 400 children with autism for the viral marker, nagalase. From my perspective this is one of the most important developments in the clinical treatment of children on the spectrum that I have experienced in the last 15 years. The short story is nearly 80% of the children with autism evaluated have significantly elevated levels of nagalase.
But what does that mean?
Virus attaching to a cell. Image credit: INST. PASTEUR/UNITE VIRUS ONCOGENES/SPL
The enzyme nagalase is produced by cancer cells and viruses. Since it is clear cancer is not feature of autism, it is most likely viral mediated enzyme activity (although in rare cases children with autism could have an undiagnosed cancer – this is unlikely). Viruses make the nagalase enzyme as part of the their attachment proteins. It serves to get the virus into the cell and also decreases the body’s immune reaction to the virus – thereby increasing the odds of viral survival.
As previously stated on this blog – the target of nagalase is the GcMAF or Vitamin D3 receptor. It is capable of inactivation this cell receptor and reducing both Vitamin D function and immune function.
It is reasonable and likely that the nature of the immune dysfunction and the frequently observed autoimmune problems in autism are mediated by persistent, unresolved viral infections.
I will write more about treatment later, but a combination of optimal dosing on Vitamin D3 and providing the GcMAF purified receptor combined with creating the ideal immune landscape for the body, seems to be extremely helpful for children with autism and elevated nagalase activity.
Neuronal stem cells are capable of migrating from the blood to the brain where they have the potential to establish repair activities. While it is not clear how much neuronal stem cells can accomplish in autism – the reports from the first 30 individual treated at the center in Kiev are certainly encouraging.
My concept of the integration of viral clearance using GcMAF followed by neuronal stem cell transplantation is about to be accomplished on the first group of children with autism whom have normalized their nagalase levels with GcMAF. Again, my overall experience to date has been extraordinarily positive with GcMAF in autism. I posted some of those outcomes in the GcMAF website (see: http://www.gcmaf.eu/info/index.php?option=com_content&view=article&id=112&Itemid=55).
I arrive in Kiev in less than 2 weeks where I will work with experienced experts with neuronal stem cells. I will keep you posted on the progress of this project as it proceeds.